FDA Grants Priority Review for Immunotherapy-Based Lung Cancer Combination – Curetoday.com
Business Wire |
FDA Grants Priority Review for Immunotherapy-Based Lung Cancer Combination
Curetoday.com “Keytruda is the first immunotherapy to significantly extend survival of patients with nonsquamous non–small cell lung cancer in combination with chemotherapy as a first-line treatment, including in patients whose tumors are either PD-L1 negative or … FDA grants priority review to Keytruda as part of non-small cell lung cancer regimen |
